HC Wainwright Reaffirms “Buy” Rating for Collegium Pharmaceutical (NASDAQ:COLL)

HC Wainwright reissued their buy rating on shares of Collegium Pharmaceutical (NASDAQ:COLL) in a research report sent to investors on Friday morning,Benzinga reports. HC Wainwright currently has a $50.00 price objective on the specialty pharmaceutical company’s stock.

COLL has been the subject of a number of other research reports. StockNews.com downgraded Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, October 23rd. Piper Sandler restated a “neutral” rating and issued a $37.00 price objective on shares of Collegium Pharmaceutical in a report on Friday, October 11th. Finally, Needham & Company LLC raised shares of Collegium Pharmaceutical from a “hold” rating to a “buy” rating and set a $46.00 target price on the stock in a research note on Friday. One research analyst has rated the stock with a hold rating and five have given a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $43.80.

Collegium Pharmaceutical Stock Down 1.3 %

COLL opened at $32.91 on Friday. The company has a market cap of $1.06 billion, a PE ratio of 14.19 and a beta of 0.82. Collegium Pharmaceutical has a twelve month low of $28.39 and a twelve month high of $42.29. The company has a 50-day moving average price of $30.57 and a 200 day moving average price of $34.04. The company has a quick ratio of 0.88, a current ratio of 0.97 and a debt-to-equity ratio of 3.43.

Hedge Funds Weigh In On Collegium Pharmaceutical

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. TD Private Client Wealth LLC increased its stake in shares of Collegium Pharmaceutical by 39.5% in the 3rd quarter. TD Private Client Wealth LLC now owns 1,707 shares of the specialty pharmaceutical company’s stock worth $66,000 after acquiring an additional 483 shares during the last quarter. Foundry Partners LLC grew its holdings in shares of Collegium Pharmaceutical by 3.3% in the third quarter. Foundry Partners LLC now owns 15,781 shares of the specialty pharmaceutical company’s stock valued at $610,000 after purchasing an additional 509 shares during the period. CWM LLC raised its stake in Collegium Pharmaceutical by 97.5% during the third quarter. CWM LLC now owns 1,491 shares of the specialty pharmaceutical company’s stock worth $58,000 after purchasing an additional 736 shares during the period. GAMMA Investing LLC raised its stake in Collegium Pharmaceutical by 124.5% during the third quarter. GAMMA Investing LLC now owns 1,428 shares of the specialty pharmaceutical company’s stock worth $55,000 after purchasing an additional 792 shares during the period. Finally, Harbor Capital Advisors Inc. grew its stake in shares of Collegium Pharmaceutical by 4.4% in the 3rd quarter. Harbor Capital Advisors Inc. now owns 23,498 shares of the specialty pharmaceutical company’s stock valued at $908,000 after buying an additional 983 shares during the period.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.